Could caffeine help save newborn brains? major trial launches
NCT ID NCT06855108
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether giving caffeine to newborns with hypoxic ischemic encephalopathy (HIE) can reduce death or long-term disability. HIE is a brain injury caused by lack of oxygen around birth. The trial will enroll 830 full-term infants and give them either caffeine or a placebo within six hours of birth. Researchers will follow the children until 18-22 months of age to compare outcomes.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- caffeine citrate oral solution
- What this could lead to
- If it works, this could provide a simple, low-cost treatment to lower the risk of death or long-term disability in newborns with HIE.
- What could go wrong
- This is an early-stage trial, and caffeine may not improve outcomes. The study is still recruiting, so results are years away.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 3
Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.
- Participants
-
About 830 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Apr 2026
- Expected to finish
-
Jul 2030
An estimate. End dates often move.
- Lead sponsor
-
A research network
The lead sponsor is a research network or cooperative group.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
Up to 6 hours
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Participant Inclusion Criteria: Infants who meet all the following criteria are eligible for enrollment as study participants: 1. Liveborn infants ≥36 weeks 2. Birth weight ≥1800 grams 3. Meets physiologic criteria for moderate to severe HIE, defined as meeting either of the following two criteria: 1. Criterion #1: Severe acidosis, defined as an umbilical cord sample or neonatal serum sample within one hour after birth demonstrating any of following criteria: * pH \<7.0; or * Base Deficit ≥16 mmol/L; or * Lactate \>8 mmol/L. 2. Criterion #2: Participant must meet all of the following three criteria: i. Moderate acidosis, defined as an umbilical cord sample or neonatal serum sample within one hour after birth demonstrating any of following criteria: * POC pH 7.0-7.15; or * Base Deficit 10.0-15.9 mmol/L; or * Lactate 6-8 mmol/L. ii. Evidence of an acute perinatal event (i.e., placental abruption, intrapartum hemorrhage, cord prolapse, severe fetal heart rate abnormality, uterine rupture). iii. Any of the following criteria: * 10-minute Apgar \<5; or * Need for assisted ventilation initiated at birth and continued for ≥10 minutes 4. Meets neurologic criteria for moderate to severe HIE, defined as a physical exam conducted between one and six hours after birth that meets either of the following criteria: 1. Moderate to severe encephalopathy in at least three out of six modified Sarnat categories (level of consciousness, spontaneous activity, muscle tone, posture, primitive reflexes, autonomic function); or 2. A clinical diagnosis of seizure in the first six hours after birth. Participant Exclusion Criteria: Infants who meet any of the following criteria are not eligible for enrollment as study participants: 1. Home births 2. Infants who cannot be enrolled, randomized and receive study medication within 6 hours post-delivery 3. Infants with a recognized major congenital anomaly or genetic syndrome that would affect their neurodevelopment. 4. Infants for whom medical care will not be provided based on the severity of their condition or any other condition that would preclude participation per clinical judgement. 5. Infant has received therapeutic hypothermia or there is a clinical plan to initiate active or passive hypothermia for the infant. 6. Infants who will be unavailable to complete follow-up visits. 7. Infants who have received caffeine after delivery. 8. Infants whom the health care team deem ineligible for the study based on likelihood to receive caffeine outside of the study protocol. 9. Enrollment in another trial that will impact participation in this trial.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Hypoxic-ischemic encephalopathy (HIE) are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
7 sites in 6 countries. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Aga Khan University
NOT_YET_RECRUITINGKarachi, Pakistan
-
ICDDR,B
RECRUITINGSaidpur, Bangladesh
-
Institute of Nutrition of Central America And Panama (INCAP)
RECRUITINGChimaltenango, Guatemala
-
KLE University's J N Medical College
NOT_YET_RECRUITINGBelagavi, India
-
Kinshasa School of Public Health
NOT_YET_RECRUITINGKinshasa, Democratic Republic of the Congo
-
Lata Medical Research Foundation
NOT_YET_RECRUITINGNagpur, India
-
University Teaching Hospital
RECRUITINGLusaka, Zambia
More trials for these conditions
Other studies related to the condition(s) this trial covers.